Infusion and Delivery Strategies to Maximize the Efficacy of CAR-T Cell Immunotherapy for Cancers

Overview

Journal Exp Hematol Oncol

Publisher Biomed Central

Specialty Hematology

Date 2024 Jul 26

PMID 39061100

Authors

Xinyu Gu

Yalan Zhang

Weilin Zhou

Fengling Wang

Feiyang Yan

Haozhan Gao

Wei Wang

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has achieved substantial clinical outcomes for tumors, especially for hematological malignancies. However, extending the duration of remission, reduction of relapse for hematological malignancies and improvement of the anti-tumor efficacy for solid tumors are challenges for CAR-T cells immunotherapy. Besides the endeavors to enhance the functionality of CAR-T cell per se, optimization of the infusion and delivery strategies facilitates the breakthrough of the hurdles that limited the efficacy of this cancer immunotherapy. Here, we summarized the infusion and delivery strategies of CAR-T cell therapies under pre-clinical study, clinical trials and on-market status, through which the improvements of safety and efficacy for hematological and solid tumors were analyzed. Of note, novel infusion and delivery strategies, including local-regional infusion, biomaterials bearing the CAR-T cells and multiple infusion technique, overcome many limitations of CAR-T cell therapy. This review provides hints to determine infusion and delivery strategies of CAR-T cell cancer immunotherapy to maximize clinical benefits.

Citing Articles

Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.

Skalickova M, Hadrava Vanova K, Uher O, Leischner Fialova J, Petrlakova K, Masarik M Front Immunol. 2025; 15:1479483.

PMID: 39850897 PMC: 11754201. DOI: 10.3389/fimmu.2024.1479483.

ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2.

Li D, Zhang W, Wang R, Xie S, Wang Y, Guo W Biomark Res. 2025; 13(1):17.

PMID: 39849645 PMC: 11756136. DOI: 10.1186/s40364-025-00730-0.

References

Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W . Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022; 32(11):995-1007. PMC: 9652391. DOI: 10.1038/s41422-022-00721-y. View

Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P . CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023; 29(11):2844-2853. PMC: 10667102. DOI: 10.1038/s41591-023-02612-0. View

Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T . Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Ann Oncol. 2018; 29(11):2163-2174. PMC: 6290929. DOI: 10.1093/annonc/mdy423. View

Papa S, Adami A, Metoudi M, Beatson R, George M, Achkova D . Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. J Immunother Cancer. 2023; 11(6). PMC: 10277526. DOI: 10.1136/jitc-2023-007162. View

Deshet-Unger N, Horn G, Rawet-Slobodkin M, Waks T, Laskov I, Michaan N . Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer. Biomedicines. 2022; 10(9). PMC: 9496506. DOI: 10.3390/biomedicines10092216. View

Xu H, Cao W, Huang L, Xiao M, Cao Y, Zhao L . Effects of cryopreservation on chimeric antigen receptor T cell functions. Cryobiology. 2018; 83:40-47. DOI: 10.1016/j.cryobiol.2018.06.007. View

Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H . IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021; 14(1):118. PMC: 8323212. DOI: 10.1186/s13045-021-01128-9. View

Liu Y, Xiao L, Joo K, Hu B, Fang J, Wang P . In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice. Biomacromolecules. 2014; 15(10):3836-45. PMC: 4195289. DOI: 10.1021/bm501166j. View

Stephan S, Taber A, Jileaeva I, Pegues E, Sentman C, Stephan M . Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2014; 33(1):97-101. PMC: 4289408. DOI: 10.1038/nbt.3104. View

10.

Williams A, Payne K, Posey Jr A, Hill C, Conejo-Garcia J, June C . Immunotherapy for Breast Cancer: Current and Future Strategies. Curr Surg Rep. 2018; 5. PMC: 5894864. DOI: 10.1007/s40137-017-0194-1. View

11.

Fitzgerald J, Weiss S, Maude S, Barrett D, Lacey S, Melenhorst J . Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med. 2016; 45(2):e124-e131. PMC: 5452983. DOI: 10.1097/CCM.0000000000002053. View

12.

Bishop M, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N . Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2021; 386(7):629-639. DOI: 10.1056/NEJMoa2116596. View

13.

Brown C, Alizadeh D, Starr R, Weng L, Wagner J, Naranjo A . Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016; 375(26):2561-9. PMC: 5390684. DOI: 10.1056/NEJMoa1610497. View

14.

Shah N, Johnson B, Schneider D, Zhu F, Szabo A, Keever-Taylor C . Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020; 26(10):1569-1575. DOI: 10.1038/s41591-020-1081-3. View

15.

Lin Y, Raje N, Berdeja J, Siegel D, Jagannath S, Madduri D . Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023; 29(9):2286-2294. PMC: 10504071. DOI: 10.1038/s41591-023-02496-0. View

16.

Tang H, Zaroudi M, Zhu Y, Cheng A, Qin L, Zhang B . Toroidal-spiral particles as a CAR-T cell delivery device for solid tumor immunotherapy. J Control Release. 2023; 362:620-630. PMC: 10947521. DOI: 10.1016/j.jconrel.2023.09.005. View

17.

Qu X, An G, Sui W, Wang T, Zhang X, Yang J . Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. J Immunother Cancer. 2022; 10(9). PMC: 9472147. DOI: 10.1136/jitc-2022-005145. View

18.

Waldmann T, Lugli E, Roederer M, Perera L, Smedley J, MacAllister R . Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood. 2011; 117(18):4787-95. PMC: 3100690. DOI: 10.1182/blood-2010-10-311456. View

19.

Katz S, Hardaway J, Prince E, Guha P, Cunetta M, Moody A . HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA liver metastases. Cancer Gene Ther. 2019; 27(5):341-355. DOI: 10.1038/s41417-019-0104-z. View

20.

Tsai C, Singh A, Xia C, Wang H . Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice. J Pharmacokinet Pharmacodyn. 2022; 49(5):525-538. PMC: 9508025. DOI: 10.1007/s10928-022-09818-8. View